Business Context and Reporting Period
TransCode Therapeutics, Inc. filed a Form 8-K on June 23, 2022, reporting matters from its annual stockholders’ meeting held June 22, 2022. The company’s common stock trades on Nasdaq under the symbol RNAZ.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes and Shareholder Votes
- All five director nominees were elected for one-year terms: Philippe P. Calais, PhD; Robert Michael Dudley; Thomas A. Fitzgerald; Erik Manting, PhD; and Magda Marquet, PhD.
- Stockholders ratified WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Of 12,977,234 shares entitled to vote, 9,100,976 shares were present or represented by valid proxy.
- Director election results included between 7,205,316 and 7,299,110 votes for each nominee, with 473,378 to 567,172 votes withheld and 1,328,488 broker non-votes.
- The auditor appointment was approved with 8,638,351 votes for, 531 against, and 462,094 abstentions; there were no broker non-votes.
Governance, Outlook, and Risks
Following the meeting, the Board consisted of the five elected directors. Philippe P. Calais, PhD chaired the Audit Committee; Magda Marquet, PhD chaired the Compensation Committee; and Erik Manting, PhD chaired the Nominating and Corporate Governance Committee. The filing provides no financial guidance, operating outlook, contingencies, or unusual financial items.
Important Facts to Verify
- Confirm the five directors’ one-year terms and committee assignments.
- Verify the shareholder vote totals and the presence of 1,328,488 broker non-votes in the director elections.
- Confirm WithumSmith+Brown, PC’s appointment for the year ending December 31, 2022.
- Review the company’s proxy statement and subsequent filings for additional governance, compensation, financial, or risk information.